Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.
Wunder F, Stasch JP, Knorr A, Mondritzki T, Brockschnieder D, Becker-Pelster EM, Sandner P, Tinel H, Redlich G, Hartung IV, Vakalopoulos A, Follmann M. Wunder F, et al. Among authors: redlich g. Br J Pharmacol. 2023 Oct;180(19):2500-2513. doi: 10.1111/bph.16142. Epub 2023 Jun 20. Br J Pharmacol. 2023. PMID: 37170767
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.
Vakalopoulos A, Wunder F, Hartung IV, Redlich G, Jautelat R, Buchgraber P, Hassfeld J, Gromov AV, Lindner N, Bierer D, Gries J, Kroh W, Paulsen H, Mittendorf J, Lang D, Becker-Pelster E, Brockschnieder D, Geiss V, Li V, Straub A, Knorr A, Mondritzki T, Trübel H, Raschke M, Schaefer M, Thomas D, Sandner P, Stasch JP, Follmann M. Vakalopoulos A, et al. Among authors: redlich g. J Med Chem. 2023 Jun 8;66(11):7280-7303. doi: 10.1021/acs.jmedchem.2c02082. Epub 2023 Apr 11. J Med Chem. 2023. PMID: 37040336
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM, Kretschmer A, Geiss V, Li V, Straub A, Mittendorf J, Jautelat R, Schirok H, Schlemmer KH, Lustig K, Gerisch M, Knorr A, Tinel H, Mondritzki T, Trübel H, Sandner P, Stasch JP. Follmann M, et al. Among authors: redlich g. J Med Chem. 2017 Jun 22;60(12):5146-5161. doi: 10.1021/acs.jmedchem.7b00449. Epub 2017 Jun 12. J Med Chem. 2017. PMID: 28557445 Free article.
Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.
Amirjanians M, Egemnazarov B, Sydykov A, Kojonazarov B, Brandes R, Luitel H, Pradhan K, Stasch JP, Redlich G, Weissmann N, Grimminger F, Seeger W, Ghofrani H, Schermuly R. Amirjanians M, et al. Among authors: redlich g. Oncotarget. 2017 May 2;8(18):29613-29624. doi: 10.18632/oncotarget.16769. Oncotarget. 2017. PMID: 28410199 Free PMC article.
Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol.
Gelevski D, Addy G, Rohrer M, Cohen C, Roderick A, Winter A, Carey J, Scalia J, Yerton M, Weber H, Doyle M, Parikh N, Kane G, Ellrodt A, Burke K, D'Agostino D, Sinani E, Yu H, Sherman A, Agosti J, Redlich G, Charmley P, Crowe D, Appleby M, Ziegelaar B, Hanus K, Li Z, Babu S, Nicholson K, Luppino S, Berry J, Baecher-Allan C, Paganoni S, Cudkowicz M. Gelevski D, et al. Among authors: redlich g. Muscle Nerve. 2023 May;67(5):354-362. doi: 10.1002/mus.27775. Epub 2022 Dec 30. Muscle Nerve. 2023. PMID: 36533976
Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
Henderson RD, Agosti JM, McCombe PA, Thorpe K, Heggie S, Heshmat S, Appleby MW, Ziegelaar BW, Crowe DT, Redlich GL. Henderson RD, et al. Among authors: redlich gl. Medicine (Baltimore). 2021 Oct 22;100(42):e27421. doi: 10.1097/MD.0000000000027421. Medicine (Baltimore). 2021. PMID: 34678870 Free PMC article. Clinical Trial.
The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers.
Ramsay JR, Suhrbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulsen MG, Baumann KC, Welburn P, Redlich GL, Parsons PG. Ramsay JR, et al. Among authors: redlich gl. Br J Dermatol. 2011 Mar;164(3):633-6. doi: 10.1111/j.1365-2133.2010.10184.x. Epub 2011 Jan 27. Br J Dermatol. 2011. PMID: 21375515 Clinical Trial.
18 results